HM
HealthCor Management Portfolio holdings
AUM
$109M
This Quarter Return
+2.02%
1 Year Return
+11.46%
3 Year Return
+50.01%
5 Year Return
+144.68%
10 Year Return
–
AUM
$1.81B
AUM Growth
-$490M
(-21%)
Cap. Flow
-$493M
Cap. Flow
% of AUM
-27.27%
Top 10 Holdings %
Top 10 Hldgs %
47.68%
Holding
96
New
23
Increased
8
Reduced
28
Closed
29
Top Buys
| 1 |
Medtronic
MDT
|
$95M |
| 2 |
Danaher
DHR
|
$49.5M |
| 3 |
Elevance Health
ELV
|
$47.1M |
| 4 |
Johnson & Johnson
JNJ
|
$46.6M |
| 5 |
Health Care Select Sector SPDR Fund
XLV
|
$35.8M |
Top Sells
| 1 |
Bristol-Myers Squibb
BMY
|
$111M |
| 2 |
McKesson
MCK
|
$94.1M |
| 3 |
Welltower
WELL
|
$50.9M |
| 4 |
Cencora
COR
|
$49.9M |
| 5 |
Zimmer Biomet
ZBH
|
$48.4M |
Sector Composition
| 1 | Healthcare | 93.43% |
| 2 | Consumer Discretionary | 2.99% |
| 3 | Financials | 1.09% |
| 4 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Syndax Pharmaceuticals
SNDX
$1.39B
| $25.3M | 1.38% |
1,157,560
-57,110
| -5% | -$1.25M |
|
|
RVNC
27
DELISTED
Revance Therapeutics, Inc.
RVNC
| $23.7M | 1.29% |
1,449,835
+1,368,335
| +1,679% | +$22.3M |
|
28
HCA Healthcare
HCA
$95.4B
| $21.7M | 1.18% |
84,270
-153,090
| -64% | -$39.3M |
|
|
LGV
29
DELISTED
Longview Acquisition Corp. II
LGV
| $21M | 1.14% |
2,135,900
| – | – |
|
30
Pfizer
PFE
$141B
| $20M | 1.09% |
+339,110
| New | +$20M |
|
31
Avantor
AVTR
$8.74B
| $18.1M | 0.98% |
+428,380
| New | +$18.1M |
|
32
Regeneron Pharmaceuticals
REGN
$59.8B
| $17.9M | 0.97% |
+28,320
| New | +$17.9M |
|
33
AbbVie
ABBV
$374B
| $16.9M | 0.92% |
+125,150
| New | +$16.9M |
|
|
34
McKesson
MCK
$85.9B
| $15.9M | 0.87% |
64,070
-378,400
| -86% | -$94.1M |
|
35
UnitedHealth
UNH
$279B
| $14.6M | 0.79% |
+29,000
| New | +$14.6M |
|
|
CANO
36
DELISTED
Cano Health, Inc.
CANO
| $14.1M | 0.77% |
15,867
-11,680
| -42% | -$10.4M |
|
37
BioMarin Pharmaceuticals
BMRN
$11.3B
| $14.1M | 0.77% |
+159,320
| New | +$14.1M |
|
38
Amgen
AMGN
$153B
| $14.1M | 0.77% |
+62,490
| New | +$14.1M |
|
|
RACB
39
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
| $12.9M | 0.7% |
1,324,800
| – | – |
|
40
Henry Schein
HSIC
$8.14B
| $9.89M | 0.54% |
+127,610
| New | +$9.89M |
|
|
IMGN
41
DELISTED
Immunogen Inc
IMGN
| $9.72M | 0.53% |
1,310,340
+1,110,340
| +555% | +$8.24M |
|
|
AFMD
42
DELISTED
Affimed
AFMD
| $9.51M | 0.52% |
172,193
-83,398
| -33% | -$4.6M |
|
|
CCXI
43
DELISTED
ChemoCentryx, Inc.
CCXI
| $8.76M | 0.48% |
+240,530
| New | +$8.76M |
|
44
Incyte
INCY
$17B
| $7.93M | 0.43% |
108,050
+33,050
| +44% | +$2.43M |
|
45
RAPT Therapeutics
RAPT
$187M
| $6.66M | 0.36% |
22,675
-413
| -2% | -$121K |
|
46
Quanterix
QTRX
$202M
| $5.7M | 0.31% |
+134,340
| New | +$5.7M |
|
|
SGEN
47
DELISTED
Seagen Inc. Common Stock
SGEN
| $5.24M | 0.29% |
+33,890
| New | +$5.24M |
|
48
Hyperfine
HYPR
$88M
| $5.01M | 0.27% |
+691,650
| New | +$5.01M |
|
49
Veracyte
VCYT
$2.41B
| $4.93M | 0.27% |
119,710
+70,070
| +141% | +$2.89M |
|
|
ARYE
50
DELISTED
ARYA Sciences Acquisition Corp V Class A Ordinary Shares
ARYE
| $4.85M | 0.26% |
500,000
| – | – |
|